The end-use landscape of the Radiopharmaceuticals Market is clearly defined, with Hospitals representing the largest segment, holding a 62% share. Hospitals are the primary users of radiopharmaceuticals due to their comprehensive diagnostic and therapeutic capabilities, specialized nuclear medicine departments, and availability of trained personnel. As primary healthcare facilities, hospitals leverage radiopharmaceuticals for both imaging procedures and therapeutic interventions, significantly contributing to their substantial market presence.

Hospitals' dominance is driven by their capacity to administer complex radioisotope therapies, including inpatient treatments requiring radiation safety infrastructure. They are the primary adopters of high-cost equipment such as PET/CT and SPECT/CT scanners, and they have the multidisciplinary teams needed to manage the full spectrum of nuclear medicine procedures. The integration of radiopharmaceuticals into both diagnostic and treatment protocols establishes a solid foundation for hospitals' market presence. Major cancer centers and academic medical centers often have dedicated radiopharmaceutical research programs, further driving utilization.

While hospitals dominate, Diagnostic Imaging Centers are the fastest-growing end-use segment, reflecting a notable shift in healthcare delivery toward outpatient settings. These specialized centers focus on imaging procedures, offering convenient access to PET/CT and SPECT scans for patients who do not require hospitalization. The growth of diagnostic imaging centers is supported by increasing demand for early cancer detection, expanding insurance coverage for advanced imaging, and patient preference for outpatient care. The segment is projected to grow from USD 2.12 billion in 2024 to USD 5.51 billion by 2035.

Research Institutions also play a vital role, focusing on clinical trials and innovative therapeutic developments. While currently holding a smaller share, research institutions are essential partners in advancing the field. They are the sites for first-in-human studies of novel radiotracers and therapies, and they contribute to the development of new radiopharmaceutical applications across disease types. The growing number of clinical trials in nuclear medicine, particularly in theranostics, is driving demand for research-grade radiopharmaceuticals. The IAEA supports research initiatives globally, fostering the development of radiopharmaceutical expertise and expanding the evidence base for new applications.

The shift toward outpatient care and the increasing availability of radiopharmaceuticals in community-based imaging centers are expected to continue, making diagnostic imaging centers a key growth area. However, hospitals will maintain their dominant position due to their comprehensive capabilities, particularly for therapeutic radiopharmaceuticals that require inpatient administration and radiation safety infrastructure.